News
FGEN
0.4450
+1.30%
0.0057
FibroGen Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 7h ago
FibroGen GAAP EPS of $0.18, revenue of $3.1M
Seeking Alpha · 8h ago
FIBROGEN INC: QTRLY NET INCOME PER SHARE $0.18
Reuters · 8h ago
FIBROGEN INC - CASH RUNWAY EXTENDED INTO 2027 UPON SALE CLOSURE
Reuters · 8h ago
Press Release: FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
Dow Jones · 8h ago
Press Release: FibroGen Reports Fourth Quarter -2-
Dow Jones · 8h ago
After-Hours Earnings Report for March 17, 2025 : BLTE, HROW, LPRO, HNRG, QTRX, DMAC, SGMO, HITI, HYPR, FGEN, RFIL, AMPS
NASDAQ · 10h ago
FibroGen: Q4 Earnings Snapshot
Barchart · 13h ago
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
Barchart · 13h ago
Here are the major earnings after the close today
Seeking Alpha · 14h ago
Weekly Report: what happened at FGEN last week (0310-0314)?
Weekly Report · 19h ago
Earnings Scheduled For March 17, 2025
Benzinga · 20h ago
Earnings week ahead: FDX, GIS, NIO, XPEV, MU, NKE, CCL, ACN and more
Seeking Alpha · 1d ago
Catalyst Watch: Nvidia event could revive animal spirits, Fed meeting, and Nike earnings
Seeking Alpha · 3d ago
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 4d ago
Weekly Report: what happened at FGEN last week (0303-0307)?
Weekly Report · 03/10 09:08
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
Barchart · 03/03 15:45
Weekly Report: what happened at FGEN last week (0224-0228)?
Weekly Report · 03/03 09:08
Aurinia Pharmaceuticals (AUPH) Beats Q4 Earnings and Revenue Estimates
NASDAQ · 02/27 12:10
FIBROGEN INC - ENTERED ATM EQUITY OFFERING SALES AGREEMENT RELATING TO SALE FROM TIME TO TIME OF SHARES OF COMMON STOCK
Reuters · 02/24 22:22
More
Webull provides a variety of real-time FGEN stock news. You can receive the latest news about Fibrogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About FGEN
More
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.